Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kelch

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Health Care Innovations : the Journal of the American Association of Preferred Provider Organizations|February 6, 1998
Consensus reached on PSO regulationsB Kelch
AAPPO Journal : the Journal of the American Association of Preferred Provider Organizations|January 8, 1993
AAPPO's legislative effortsM Merz, B Kelch
Industry and Health Care|December 13, 1978
Industry and insurer interventions to control the costs of health benefitsW J Bicknell, B Kelch
Clinical Nephrology|November 1, 1992
RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapyA B Schwartz, S B Kahn, B Kelch, et al.
ASAIO Transactions|July 1, 1990
One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysisA B Schwartz, B Kelch, L Terzian, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Health Care Innovations : the Journal of the American Association of Preferred Provider Organizations|February 6, 1998
Consensus reached on PSO regulationsB Kelch
AAPPO Journal : the Journal of the American Association of Preferred Provider Organizations|January 8, 1993
AAPPO's legislative effortsM Merz, B Kelch
Industry and Health Care|December 13, 1978
Industry and insurer interventions to control the costs of health benefitsW J Bicknell, B Kelch
Clinical Nephrology|November 1, 1992
RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapyA B Schwartz, S B Kahn, B Kelch, et al.
ASAIO Transactions|July 1, 1990
One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysisA B Schwartz, B Kelch, L Terzian, et al.
Pageof 1